Status:
TERMINATED
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
Bausch Health Americas, Inc.
Conditions:
Hepatic Encephalopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective study designed to examine the role of bacterial overgrowth and delayed intestinal transit and the effect of Rifaximin with hepatic encephalopathy (HE). This study is divided into...
Detailed Description
This is a prospective study designed to examine the role of bacterial overgrowth and delayed intestinal transit and the effect of Rifaximin with hepatic encephalopathy (HE). This study is divided into...
Eligibility Criteria
Inclusion
- Ambulatory patients with HCV cirrhosis will be screened for participation in the study
- Ability to complete Number Connection Test
- Creatinine \<1.5mg/dL
- Able to provide informed consent
- Patients determined to possibly meet the West Haven criteria grade 0 or 1 for HE
Exclusion
- Active interferon therapy
- History of alcohol abuse within six months
- Active gastrointestinal bleeding
- Use of agents that alter intestinal motility, e.g., methadone, cholestyramine, Tricyclic antidepressants, etc.
- Use of Neomycin or other antibiotics within the past 2 weeks
- Pregnancy
- Unable to provide informed consent
Key Trial Info
Start Date :
September 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01846806
Start Date
September 1 2012
End Date
March 1 2016
Last Update
August 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Medical Center
New York, New York, United States, 10016